Background illustration for clinical trials search

Non-Alcoholic Steatohepatitis (NASH) Clinical Trials

Browse 141 non-alcoholic steatohepatitis (nash) clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

NAFLD Clinical Care Pathway

for
NAFLD, MASLD
Location: Houston TX
Sponsor: VA Office of Research and Development

Sex: All

Age: 18 - 70+

Code: NCT06671886

Recruiting

Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis

for
Liver Steatoses, Liver Metastasis Colon Cancer, NAFLD
Location: London
Sponsor: Anton Skaro

Sex: All

Age: 18+

Code: NCT05884723

Recruiting

Thermoacoustic Method for Estimating Liver Fat Fraction

for
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis),
Location: Ann Arbor MI
Sponsor: Endra Lifesciences

Sex: All

Age: 18+

Code: NCT07321925

Recruiting

Digoxin In NASH (CODIN)

for
NASH, NAFLD,
Location: New Haven CT
Sponsor: Yale University

Sex: All

Age: 18 - 70+

Code: NCT06588699

Phase 2, Recruiting

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

for
Metabolic Associated Fatty Liver Disease,
Location: Miami FL, Columbus OH, Bellaire TX, San Antonio TX
Sponsor: Foundation for the National Institutes of Health

Sex: All

Age: 18 - 70+

Code: NCT07122700

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

for
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD),
Location: Sherbrooke
Sponsor: Université de Sherbrooke

Sex: All

Age: 20 - 70+

Code: NCT06843148

Recruiting
New

Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

for
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Location: Miami FL, Marrero LA, Metairie LA, Georgetown TX
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT07854782

Phase 3, Recruiting
New

Resmetirom in Patients With MASH and HFpEF

for
MASH - Metabolic Dysfunction-Associated Steatohepatitis,
Location: Fort Myers FL, Riverview FL, University Park FL,
Sponsor: Madrigal Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07830758

Phase 1, Recruiting

Quantitative Ultrasound to Assess Steatotic Liver Disease in Children

for
MASLD,
Location: La Jolla CA
Sponsor: University of California, San Diego

Sex: All

Age: 9 - 18

Code: NCT06706856

Recruiting

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

for
MASLD, Obesity
Location: Albuquerque NM
Sponsor: University of New Mexico

Sex: All

Age: 18 - 70+

Code: NCT06934642

Early Phase 1, Recruiting

Efficacy of an Amniotic Fluid Derived Allograft, (FlōGraft®) in Rotator Cuff Repairs: A Prospective Study

for
Rotator Cuff Tear, Fatty Atrophy
Location: Houston TX
Sponsor: Applied Biologics, LLC

Sex: All

Age: 0+

Code: NCT03379324

Recruiting

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

for
NASH - Nonalcoholic Steatohepatitis
Location: New York NY, Richmond VA, Charlottesville VA,
Sponsor: Perspectum

Sex: All

Age: 18 - 70+

Code: NCT04054310

Recruiting

Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US

for
Liver Fibrosis, Fatty Liver
Location: New York NY
Sponsor: New Discovery LLC

Sex: All

Age: 18+

Code: NCT06051669

Recruiting

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

for
Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis,
Location: Scottsdale AZ
Sponsor: Mayo Clinic

Sex: All

Age: 30 - 70

Code: NCT04232566

Recruiting

Early Tracking of Childhood Health Determinants (ETCHED) Study

for
Diabetes Mellitus, Obesity, Fatty Liver
Location: Phoenix AZ
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Sex: All

Age: 0 - 70+

Code: NCT03481829

Recruiting

High Fructose Diet, the Gut Microbiome, and Metabolic Health

for
MASLD, Type 2 Diabetes, Obesity
Location: New York NY
Sponsor: Icahn School of Medicine at Mount Sinai

Sex: All

Age: 25 - 45

Code: NCT06329544

Recruiting

A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects

for
Non-Alcoholic Steatohepatitis (NASH)
Location: Secaucus NJ
Sponsor: Hepanova Inc.

Sex: All

Age: 18 - 55

Code: NCT04481594

Phase 1, Recruiting

Effect of Polyphenol Supplementation on Hepatic Steatosis and Vascular Compliance

for
Obesity, Childhood, Hepatic Steatosis, Intimal Hyperplasia
Location: Montreal
Sponsor: St. Justine's Hospital

Sex: All

Age: 12 - 18

Code: NCT03994029

Recruiting

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

for
Healthy Volunteers,
Location: Miami FL, Marrero LA, Houston TX, Los Angeles CA
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT05648214

Phase 1, Phase 2, Recruiting

Corazones Unidos Study

for
CVD - Cardiovascular Disease,
Location: Tucson AZ
Sponsor: University of Arizona

Sex: All

Age: 18+

Code: NCT07298213

Recruiting

What is NASH (MASH)?

NASH stands for nonalcoholic steatohepatitis. In 2023, liver experts renamed it MASH, metabolic dysfunction associated steatohepatitis, because it is driven by things like excess weight, type 2 diabetes, high blood pressure, and high cholesterol. It is the same disease, and many doctors and studies still use both names. It starts as fatty liver disease, where extra fat builds up in liver cells. In some people the fat causes inflammation and damage, and that is MASH. The damage can slowly turn into scarring, called fibrosis, and in some people into cirrhosis.

It is a common problem. Yale Medicine estimates that 6 to 8 million Americans have NASH with moderate to advanced liver scarring. And most of them do not know it, because the disease usually causes no symptoms until the liver is badly damaged. The first medicine approved for it, Rezdiffra (resmetirom), arrived in March 2024. The second, Wegovy (semaglutide), was approved for MASH in August 2025. Both got accelerated approval, which means larger studies are still checking whether they prevent cirrhosis and other serious problems over time.

Article preview image

Our guide to fatty liver treatment options explains more.

What Actually Works for Fatty Liver, According to the Trials

The stages of liver scarring in NASH (MASH)

Types of NASH (MASH) clinical trials

Who can participate in NASH (MASH) clinical trials?

Do NASH (MASH) trial participants get paid?

How to enroll in a NASH (MASH) clinical trial